Announced Date: 2025-08-29 (August 29, 2025)
Asset Name: KY-0301
Licensor: Novatim (Novatim Immune Therapeutics, China)
Licensee (Buyer): Radiance (Radiance Biopharma, US)
.
Asset Modality: BsADC (bispecific antibody drug conjugate) , nanobody
Asset Target: MET/EGFR
Potential Indication: solid tumors
Current Stage: Phase I, in China
.
Scope of Authority:
Novatim has granted Radiance exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize KY-0301.
.
Deal Detail:
Upfront payment of $15 million,
Development and regulatory milestone payments up to $150 million;
Sales milestone payments of up to $1 billion.
Total up to $1.165 billion.
Tiered royalties on net sales.
.
